Rheumatic Pain
Conditions
Brief summary
The purpose of this study is to evaluate the effect of Panax Notoginseng Powders on Rheumatic Pain.
Interventions
DIETARY_SUPPLEMENTPanax Notoginseng Powder 15g
DRUGCelecoxib Capsule 400 mg daily
DIETARY_SUPPLEMENTPanax Notoginseng Powder 1g
DIETARY_SUPPLEMENTPanax Notoginseng Powder 5g
DIETARY_SUPPLEMENTPanax Notoginseng Powder 10g
Sponsors
Chengdu PLA General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* had a diagnosis of classic or definite RA * without conflict to the written, informed consent signed prior to the enrollment.
Exclusion criteria
* uncontrolled medical problems * organic brain syndrome * major psychiatric disturbances * major communicative disorders * a history of severe noncompliance * less than 7 years of formal education, or illiteracy * being included in other clinical trial within the last 4 weeks * with abnormal liver or kidney function (more than 1 time above the high normal) * with serious cardiovascular disease * with hematologic disease * being in pregnancy, lactation period or under a pregnancy plan * with severe gastrointestinal disease * with contraindication or being allergic to the test drugs * being under the treatment of drugs within 1 previous week, that might affect the results of the trial, such as non-steroidal anti-inflammatory drugs * being not compatible for the trial medication, or other circumstances at the discretion of investigators * without legal capacity or only with limited legal capacity
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline in McGill Pain Questionnaire (MPQ) score at 24 weeks | at 0 week, 6 weeks, 12 weeks, 24 weeks | This well validated questionnaire assesses pain on several dimensions including sensory pain, affective pain, and evaluative pain. |
| Change from Baseline in Visual Analog Scale(VAS) score at 24 weeks | at 0 week, 6 weeks, 12 weeks, 24 weeks | This rating scale involved the selection of a point along a 10-cm line, which described pain intensity on a continuum from no pain at all to pain as bad as it could be. This scale has been found to be an excellent measure of self-reported pain |
Countries
China
Outcome results
None listed